Selected Publications

MEDICAL JOURNALS

GUEST BLOGS

Are Americans changing their eating and drinking habits under COVID-19?

JULY 9, 2020

By Andres Digenio, MD, PhD

When trying to lose weight not everything is your fault!

JULY 22, 2020

By Andres Digenio, MD, PhD

To hug or not to hug?

August 6, 2020

By Andres Digenio, MD, PhD

You don’t have to become a couch potato through the pandemic!

August 6, 2020

By Andres Digenio, MD, PhD

Comparison of Methods for Delivering a Lifestyle Modification Program for Obese Patients: A Randomized Trial

Digenio AG, Mancuso J, Gerber R, Dvorak R. Comparison of Five Different Methods of Delivering a Lifestyle Modification Program for Weight Loss in Obese Patients Taking Sibutramine. A Randomized Trial. Ann Intern Med. 2009;150:255-262.

https://pubmed.ncbi.nlm.nih.gov/19221377/

Prandial Insulin Versus Glucagon-Like peptide-1 Added to Basal Insulin: Comparative Effectiveness in the Community Practice Setting

Digenio A, Karve S, Candrilli SD, Dalal M. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. Postgrad Med. 2014 Oct; 126(6): 49-59.

https://pubmed.ncbi.nlm.nih.gov/25414934/

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Digenio AG, Dunbar RL, Alexander VJ, et al. Antisense Mediated Lowering of Plasma Apolipoprotein CIII by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care. 2016 Aug;39(8):1408-15. 

https://pubmed.ncbi.nlm.nih.gov/27271183/

Maximizing Retention in Long-Term Clinical Trials of a Weight Loss Agent: Use of a Dietitian Support Team

Delahanty LM, Riggs M, Klioze SS, Chew RD, England RD and Digenio A. Maximizing retention in long-term clinical trials of a weight loss agent: use of a dietitian support team. Obes Sci Pract. 2016 Sep;2(3):256-265.  

https://pubmed.ncbi.nlm.nih.gov/27708842/

Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B Rx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes

Digenio A, Pham NC, Watts LM et al. Antisense Inhibition of Protein Tyrosine Phosphatase-1B with IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients with Type 2 Diabetes. Diabetes Care 2018 Apr; 41(4): 807-814.

https://pubmed.ncbi.nlm.nih.gov/29439147/

The protective measures in the new normal work

JUNE 10, 2020 

By Andres Digenio, MD, PhD

You don’t have to live on junk food during the COVID-19 pandemic!

August 11, 2020

By Andres Digenio, MD, PhD